Welcome to our dedicated page for Cypherpunk Technologies SEC filings (Ticker: CYPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cypherpunk Technologies Inc. (CYPH) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation listed on the Nasdaq Capital Market, Cypherpunk reports material events, capital structure changes, and governance decisions through current reports on Form 8-K and related exhibits.
In its 8-K filings, Cypherpunk has documented key steps in its transition from Leap Therapeutics, Inc. to Cypherpunk Technologies Inc., including actions approved at a special meeting of stockholders. One 8-K describes stockholder approval of an amendment to the certificate of incorporation to increase authorized share capital, a reverse stock split proposal, adoption of the 2025 Equity Incentive Plan, a private placement issuance proposal, and authorization to adjourn the meeting if needed. The same filing notes that Nasdaq confirmed the company had regained compliance with its minimum bid price listing requirement.
Another 8-K details a Waiver and Modification Agreement between Cypherpunk and Winklevoss Treasury Investments, LLC related to a warrant issued in connection with a private placement led by Winklevoss Capital. This filing explains how certain warrant share reservation requirements were waived to make shares available for potential issuance under the company’s at-the-market equity offering program and specifies conditions affecting when those warrant shares may be exercised.
Through these and other filings accessible via EDGAR, investors can review how Cypherpunk structures its equity incentives, manages authorized share levels, and documents financing arrangements tied to its Zcash-focused digital asset treasury strategy and ongoing operations. Stock Titan’s integration of real-time EDGAR updates and AI-powered summaries is designed to help readers quickly understand the implications of Cypherpunk’s 8-Ks, charter amendments, equity plans, and other SEC reports without having to parse every technical detail themselves.
Schilsky Richard reported acquisition or exercise transactions in this Form 4 filing.
Cypherpunk Technologies director Richard Schilsky increased his equity stake through RSU settlements, not open-market buying. On March 13, 2026, 74,700 Restricted Stock Units granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were each settled 1-for-1 into common shares for no cash consideration. Both RSU awards had vested at issuance. Following these conversions, Schilsky directly holds 168,750 shares of Cypherpunk Technologies common stock as reported in the filing.
Cypherpunk Technologies director Joseph Loscalzo acquired 168,750 common shares through RSU settlements. On March 13, 2026, 74,700 RSUs granted on November 11, 2025 and 94,050 RSUs granted on December 23, 2025 were each settled on a 1-for-1 basis for common stock at no cash exercise price.
Both RSU grants had vested at issuance under the company’s 2022 and 2025 Equity Incentive Plans, and this Form 4 shows a compensation-related derivative exercise rather than any open-market buying or selling. Following these transactions, Loscalzo directly holds 168,750 shares of Cypherpunk common stock with no remaining RSU position reported.
Cypherpunk Technologies Inc. director James H. Cavanaugh acquired shares through the settlement of previously granted restricted stock units (RSUs). On March 13, 2026, 74,700 November 2025 RSUs and 94,050 December 2025 RSUs each settled on a 1-for-1 basis into common stock, totaling 168,750 shares.
These RSUs were granted for no cash consideration under the company’s 2022 and 2025 equity incentive plans and had vested at issuance. After these non‑cash, compensation-related exercises/conversions, Cavanaugh directly owned 168,963 shares of Cypherpunk common stock, with no open‑market buying or selling reported in this filing.
Cypherpunk Technologies Inc. reports a transformed business model that combines a privacy-focused digital asset strategy with ongoing cancer drug development. The company changed its name from Leap Therapeutics to reflect a new emphasis on Zcash, a privacy-preserving blockchain network and digital asset.
Cypherpunk is accumulating ZEC as a digital asset treasury; as of March 11, 2026 it held 294,743.10 ZEC at an average purchase price of $335.89, about 1.76% of circulating supply, with a goal of reaching at least 5% over time. The firm also invested $5 million in Zcash Open Development Lab to support the core Zcash wallet and protocol development.
Through its Leap Therapeutics subsidiary, the company continues to develop sirexatamab (DKN-01) for colorectal cancer and other indications, with Phase 2 data showing higher response rates and longer progression-free survival in biomarker-selected patients. A second program, FL-501, targets GDF-15 for cachexia and related conditions. Extensive patent portfolios and licensing agreements with Eli Lilly and Adimab underpin its biotechnology assets.
Cypherpunk Technologies reported a sharp turnaround for 2025, posting net income of $4.8 million after a net loss of $67.8 million in 2024. Results were driven mainly by a $50.4 million unrealized gain on the fair value of its Zcash (ZEC) digital asset treasury.
Operating expenses fell as research and development dropped to $25.7 million and general and administrative to $10.9 million, helped by reduced clinical and payroll costs following completion of the sirexatamab Phase 2 program and headcount reductions. At year-end 2025, cash and cash equivalents were $14.0 million, while ZEC treasury holdings recorded as a digital asset receivable totaled $147.4 million, reflecting the company’s new privacy-technology and Zcash-focused strategy funded by a prior $58.88 million private placement.
Cypherpunk Technologies Inc. received a notice from Nasdaq that its common stock has closed below the required $1.00 per share minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq Listing Rule 5550(a)(2).
The notice is a deficiency warning, not an immediate delisting, and the stock continues to trade on the Nasdaq Capital Market. The company has 180 days, until August 31, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for 10 straight business days, and may qualify for an additional 180-day period if other listing standards are met.
Cypherpunk plans to monitor its share price and may pursue options such as a reverse stock split to restore compliance, but there is no assurance it will succeed within the initial or any additional compliance period.
Cypherpunk Technologies Inc. (CYPH) is the subject of an amended Schedule 13G filing by Gilead Sciences, Inc. covering its holdings of Cypherpunk common stock, par value $0.001 per share, CUSIP 52187K200.
Gilead now reports beneficial ownership of 0 shares of Cypherpunk common stock, representing 0% of the class, with no sole or shared voting or dispositive power. The filing states that Gilead's ownership is now "5 percent or less" of the class.
Gilead certifies that any securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cypherpunk, nor in connection with any transaction intended to have that effect.
Cypherpunk Technologies Inc. reported results of a special stockholder meeting and an update on its stock exchange listing. Stockholders approved a new 2025 Equity Incentive Plan that allows up to 31,454,785 shares of common stock to be covered by grants. They also approved amending the company’s charter to increase authorized shares from 250,000,000 to 500,000,000, with 490,000,000 designated as common stock and 10,000,000 as preferred stock, and to add clarifying language tied to Delaware law changes.
Stockholders further approved a reverse stock split proposal, a private placement issuance proposal, and the potential adjournment of the special meeting, with all measures receiving strong majorities. Separately, the company received notice from Nasdaq on December 11, 2025 that it had regained compliance with the minimum $1.00 bid price listing requirement, closing a prior deficiency matter.
Cypherpunk Technologies Inc. (CYPH) insiders reported an internal transfer of derivative securities. Winklevoss-affiliated entities filed a Form 4 showing an assignment of warrants for no additional consideration, representing rights to buy 5,616,906 shares of common stock. The warrants are exercisable immediately and expire on 10/08/2035, with an exercise price of $0.5335 per share.
Following the transaction, the reporting persons indirectly beneficially own 57,182,378 warrants through Winklevoss Treasury Investments, LLC. Warrant exercises are limited so that the reporting group’s beneficial ownership does not exceed 19.99% of Cypherpunk’s outstanding common stock after any exercise.
CYPHERPUNK TECHNOLOGIES INC. insider Winklevoss-affiliated entities filed an initial Form 3 reporting significant ownership in CYPH. The filing shows indirect beneficial ownership of 8,283,761 shares of common stock held through Winklevoss Treasury Investments, LLC. It also reports a Pre-Funded Warrant exercisable for 75,448,618 shares of common stock at an exercise price of $0.001 per share, with no expiration date, and an additional Warrant for 62,799,284 shares at an exercise price of $0.5335 per share expiring on 10/08/2035.
Both the Pre-Funded Warrants and the Warrants are immediately exercisable but include a 19.99% beneficial ownership limitation, preventing exercises that would cause the reporting group and its affiliates to exceed 19.99% of CYPHERPUNK’s outstanding common stock after any exercise.